Related Experiment Video
Updated: Nov 11, 2025
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.7K
Novel adjuvant options for cutaneous melanoma
F Dimitriou1, G V Long2, A M Menzies2
1Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Summary
Adjuvant immunotherapy and targeted therapy significantly improve recurrence-free survival for resected stage III and IV melanoma patients. Further research is needed to optimize treatments and reduce toxicity.
Area of Science:
- Oncology
- Dermatology
- Immunotherapy
Background:
- Resected stage III and IV melanoma patients face a high risk of recurrence.
- Systemic therapies have improved outcomes for metastatic melanoma.
- Checkpoint inhibitor immunotherapy and targeted therapy offer new adjuvant treatment options for early-stage melanoma.
Purpose of the Study:
- To review the latest clinical trial data on adjuvant treatments for early-stage melanoma.
- To outline the current adjuvant treatment landscape and its clinical application.
- To discuss expected future progress in managing early-stage melanoma.
Main Methods:
- Review of latest clinical trial data.
- Analysis of current adjuvant treatment landscape.
- Discussion of clinical practice and future progress.
Main Results:
- Anti-programmed cell death protein 1 monotherapy and BRAF/MEK inhibitors are standard for resected stage III melanoma.
- Adjuvant treatment is recommended for stage IIIB-IIID melanoma (AJCCv8) and considered for stage IIIA.
- Nivolumab is approved for resected stage IV melanoma; combined ipilimumab and nivolumab show promise.
Conclusions:
- Immunotherapy and targeted therapy improve recurrence-free survival compared to placebo/ipilimumab.
- Prognostic and predictive biomarkers are needed to optimize treatments.
- Strategies to reduce toxicity and overcome resistance are essential for improving patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
820
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
820
01:30Skin Cancer
5.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.1K
01:30Cancer Vaccines
610
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
610
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K